11 May 2016
China has approximately a third of the world’s diabetes patients, and type 2 diabetes accounts for 90% of all diabetes incidence. Datamonitor Healthcare estimates that there were 110 million type 2 diabetes patients in China in 2013, and that the number of patients will reach 131 million in 2021, representing a 19.1% increase. The substantial patient base makes China an attractive market for existing and future market entrants.
Datamonitor Healthcare’s type 2 diabetes patient-based forecast is segmented by brand and tier 1, tier 2a, tier 2b and tier 2c cities in China from 2012-2021. Treatment, dosing, pricing and future event assumptions are added to create Datamonitor Healthcare’s forecast
Key questions answered in this analysis
- What will the value of the type 2 diabetes market in China be by 2021?
- What is the reimbursement process in China and how could this affect your market entry?
- What will be the effect of compulsory price cuts on sales growth over the forecasted period?
- How will the addition of dipeptidyl-peptidase-IV inhibitor and glucagon-like peptide-1 agonist classes to the Nation Reimbursement Drug List effect the type 2 diabetes market in China?
Therapy classes covered in this analysis
- Alpha-glucosidase inhibitor (AGI)
- Dipeptidyl peptidase-IV (DPP-IV) inhibitor
- Long-acting insulin + short acting insulin
- Premixed insulin
- Glucagon-like peptide-1 (GLP-1) agonist
- Short-acting insulin
- Human insulin
- Long-acting insulin
- Thiazolidinedione (TZD)
- Sodium-glucose cotransporter-2 (SGLT-2) inhibitor